DIANA assay

Technology description

The name of the technology:	DIANA assay
Challange:	Many proteins are functionally related to cancerogenesis. Reliable quantification of these proteins in human serum or tissue biopsy samples represents a way to assess better diagnosis and improve patient outcome. Moreover, small molecule drugs inhibiting biological function of these proteins are also used in cancer therapy. Here we present a newly developed assay, called DIANA, which is capable of both selective protein detection and screening of small molecule inhibitors of those proteins.
Description:	DIANA is a multiwell-plate based sandwich ELISA-like dual recognition assay, suitable for protein detection and screening of protein ligands that employs a fully synthetic detection probe. This probe is constructed from small molecule active site ligand and it consequently binds into the active site of the target protein. Advantages of DIANA for protein detection: - Sensitivity: up to zeptomolar amounts of target proteins are detected - Selectivity: target proteins are selectively quantified in biological matrices (blood serum, urine, cell lysate) - Broad linear range of up to six-logs Advantages of DIANA for screening of small molecule ligands: - Sensitivity: only small amounts of protein needed for screening - Selectivity: no need for recombinant and/or purified proteins - Dissociation constant can be determined from single tested concentration
Commercial opportunity:	We have developed an ultrasensitive and selective ELISA-like assay for detection of target proteins in biological matrices with linear range of up to six logs. Moreover, the assay is suitable for accurate, quantitative and sensitive high-throughput screening of small molecule ligands on unpurified target proteins, most notably of competitive inhibitors of enzymes. Currently, we look for a business partner, who might be interested in the collaborative commercial exploitation of the assay.
IP protection status:	CZE patent application filed 2014, PCT application filed 2015
Development status:	Phase 3 Corresponds with TRL 5 and TRL 6 Technology validation and implementing it in real environment. Testing the technology outside of the laboratory and its adjustment to external conditions. TRL 5 represents a state where the results of the real environment tests are known and there is an idea of how to deal with the problems found (if any) TRL 6 is a state where a fully functional prototype already exists and is capable of fulfilling all its functions
Partnering strategy:	Collaboration investment licensing
Další informace:	DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening; Navrátil V, Schimer J, Tykvart J, Knedlík T, Vik V, Majer P, Konvalinka J, Šácha P.; Nucleic Acids Res. 2016 Sep 26 https://www.dianabiotech.com/ https://youtu.be/hrh82euICfU
Images:	No picture inserted
Keywords:	diagnostics
Categories:	Research Tools Diagnostics Life Science and Health
Owner of a technology:
Institution:	i&i Prague